ASC-US
8
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients With High-Risk HPV (Hr-HPV) and Either (1) ASC-US or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL)
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
Study of Treatment for HPV16+ ASC-US or LSIL
Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
"Lactobacillus Crispatus M247, LSIL and Microbiota"
Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS?
HPV Test of Urine and Self Collected Vaginal Samples for Cervical Cancer Screening Study
Probiotic Implementation as Help in Solving Vaginal Infections